登录 | 注册    关注公众号  
微信公众号
搜索
 > 【Glycoprotein / GP (virus)】

Glycoprotein / GP (virus)信息

英文名称:Envelope glycoprotein
中文名称:包膜糖蛋白
靶点别称:GP1,2,GP,Envelope glycoprotein
上市药物数量:2
临床药物数量:2
最高研发阶段:批准上市

Glycoprotein / GP (virus)分子别名

GP,Envelope glycoprotein,GP(1,2)

Glycoprotein / GP (virus)分子背景

EBOV encodes seven structural proteins: nucleoprotein (NP), polymerase cofactor (VP35), (VP40), GP, transcription activator (VP30), VP24, and RNA polymerase (L). GP protein contains 160-kDa envelope-attached glycoprotein (GP) and a 110 kDa secreted glycoprotein (sGP). GP is a class I fusion protein which assembles as trimers on viral surface and plays an important role in virus entry and attachment. Mature GP is a disulfide-linked heterodimer formed by two subunits, GP1 and GP2, which are generated from the proteolytical process of GP precursor (pre-GP) by cellular furin during virus assembly . GP1 is responsible for binding to the receptor(s) on target cells. Interacts with CD209/DC-SIGN and CLEC4M/DC-SIGNR which act as cofactors for virus entry into the host cell. GP2 acts as a class I viral fusion protein. GP1,2 mediates endothelial cell activation and decreases endothelial barrier function. sGP seems to possess an anti-inflammatory activity as it can reverse the barrier-decreasing effects of TNF alpha.

Glycoprotein / GP (virus)上市药物信息

英文名称 中文名称 研发代码 研发阶段 公司 最早商品名 最早批准国家 最早适应症 最早批准公司 最早批准日期 适应症 临床试验
Atoltivimab/Maftivimab/Odesivimab REGN3470-3471-3479; REGN-EB3 批准上市 Regeneron Pharmaceuticals Inc Inmazeb United States 埃博拉病毒性疾病 Regeneron Pharmaceuticals Inc 2020-10-14 埃博拉病毒性疾病 详情
Ansuvimab 安舒韦单抗 VRC-EBOMAB092-00-AB; MAb114; MAb-114 批准上市 National Institute Of Allergy And Infectious Diseases (Niaid), National Institute of Health, Islamabad Ebanga United States 埃博拉病毒性疾病 Ridgeback Biotherapeutics Lp 2020-12-21 埃博拉病毒性疾病 详情

Glycoprotein / GP (virus)临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
Porgaviximab/Larcaviximab/Cosfroviximab c2G4-N; c4G7; c13C6 临床三期 Mapp Biopharmaceutical, 加拿大国家微生物实验室公共卫生署 埃博拉病毒性疾病 详情
MIL-77 MIL-77 临床一期 北京天广实生物技术股份有限公司, 浙江海正药业股份有限公司, 军事医学科学院基础医学研究所 埃博拉病毒性疾病 详情

消息提示

请输入您的联系方式,再点击提交!

确定